Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00820222. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
Study identification
- NCT ID
- NCT00820222
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 540 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2009 (Actual)
- Primary completion
- Jun 11, 2012 (Actual)
- Completion
- Mar 22, 2018 (Actual)
- Last update posted
- Apr 2, 2019
2009 – 2018
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Goodyear | Arizona | 85338 | — |
| Novartis Investigative Site | Tucson | Arizona | 85715 | — |
| Novartis Investigative Site | Jonesboro | Arkansas | 72401 | — |
| Novartis Investigative Site | Anaheim | California | 92801 | — |
| Novartis Investigative Site | Greenbrae | California | 94904-2007 | — |
| Novartis Investigative Site | Sacramento | California | 95816 | — |
| Novartis Investigative Site | Santa Barbara | California | 93105 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20007 | — |
| Novartis Investigative Site | Boca Raton | Florida | 33486 | — |
| Novartis Investigative Site | Coral Springs | Florida | 33065 | — |
| Novartis Investigative Site | Hollywood | Florida | 33021 | — |
| Novartis Investigative Site | Warrenville | Illinois | 60555 | — |
| Novartis Investigative Site | Metairie | Louisiana | 70006 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Great Falls | Montana | 59405 | — |
| Novartis Investigative Site | Voorhees Township | New Jersey | 08043 | — |
| Novartis Investigative Site | Durham | North Carolina | 27710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 147 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00820222, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2019 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00820222 live on ClinicalTrials.gov.